On July 2, 2022, Mgi Tech Co., Ltd (hereinafter referred to as MGI) and Guangzhou Burning Rock Biotech Co., Ltd. (hereinafter referred to as "BNR") officially reached a strategic cooperation, and BNR will develop and apply related oncology medical products based on MGI Intelligent Manufacturing's core sequencing technology DNBSEQ™ to promote the clinical application of tumor precision medicine.

According to the cooperation agreement, BNR will provide related commercial services and IVD product development based on but not limited to the high-throughput sequencers MGISEQ-2000 and DNBSEQ-T7 equipped with DNBSEQ™ sequencing technology. MGI will also provide corresponding technical support and services.

About BNR

Burning Rock Medicine (NASDAQ: BNR) was established in 2014 with the aim of "protecting the light of life with science", focusing on providing clinically valuable next-generation gene sequencing (NGS) for precision tumor medicine. The company's business and research and development directions mainly cover:

1)     Precise medical detection of cancer patients.

2)     Collaboration on biomarkers and companion diagnostics for global oncology pharmaceutical companies.

3)     Early detection of multiple cancers. In July 2018, Burning Rock was awarded the first certificate of China's tumor NGS detection kit by the National Medical Products Administration (NMPA), which is a milestone in the field of in vitro diagnosis. The laboratory in Guangzhou, China has passed the technical audit of "High-throughput Sequencing Laboratory" issued by the Guangdong Provincial Clinical Laboratory Center and obtained the US CLIA and CAP laboratory quality system certification; the laboratory in California, the US has also obtained CLIA and CAP Laboratory quality system qualification certification. The company will continue to develop innovative and reliable NGS detection products to promote the development of precision tumor medicine